| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2017: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the effect of the combined immunotherapy with the cancer vaccine using dendritic cells (DC) and the immune checkpoint inhibitor. In in vitro experiment, induction of cytotoxic T lymphocytes (CTLs) against WT1, which was reported to be expressed in oral squamous cell carcinoma cells, was enhanced by the combined use of anti-PD-1 antibody. In in vivo study using syngeneic tumor-bearing mice, stronger anti-tumor effect was observed by the treatment with WT1 pulsed DC vaccine and anti-PD-1 antibody as compared with DC vaccine alone or anti-PD-1 antibody alone. We conducted a pilot study of the combination therapy with anti-PD-1 antibody + cancer antigen pulsed DC vaccine. Up to now, 6 patients with unresectable oral cancer have been treated with the same method and are under observation. In all cases, induction of CTL specific for at least one cancer antigen used was confirmed. We plan to continue expanding the number of cases.
|
